Tag Archives: Roth Capital

Analyst Maintains Buy Rating on Depomed Inc (DEPO), Following Nucynta Performance Satisfactory

Healthcare

In a research report released to investors yesterday, analyst Scott Henry from Roth Capital reiterated his Buy rating on the specialty pharmaceutical company Depomed Inc (NASDAQ: DEPO), with a price target of $27. This PT is an upside of 36.57% from

Roth Capital Believes DEPO Won’t Stop Here

Roth Capital analyst Scott Henry reiterated a Buy rating on Depomed (NASDAQ: DEPO) today and set a price target of $28. The company’s shares opened today at $25.50, close to its 52-week high of $27.02. Henry said, “We view this

Roth Capital Believes HEOFF Still Has Room to Grow

In a report released yesterday, Gerry Sweeney from Roth Capital maintained a Buy rating on H2O Innovation (NYSE: HEOFF). The company’s shares closed yesterday at $1.39, equals to its 52-week high of $1.39. According to TipRanks.com, Sweeney is a 3-star

Analysts Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 experts just weighed in on Regeneron (NASDAQ: REGN) and Natus Medical Inc. (NASDAQ: BABY) with bullish sentiments. Regeneron (NASDAQ: REGN) In a report released today, Joseph Pantginis

Roth Capital Believes INTC Still Has Room to Grow

In a report released today, Sujeeva De Silva from Roth Capital maintained a Buy rating on Intel Corp. (NASDAQ: INTC), with a price target of $43. The company’s shares opened today at $37.69, close to its 52-week high of $38.05.

Maxwell Technologies Receives a Hold from Roth Capital

Roth Capital analyst Craig Irwin reiterated a Hold rating on Maxwell Technologies (NASDAQ: MXWL) today and set a price target of $5. The company’s shares opened today at $5.11. Irwin wrote, “We hosted meetings with Maxwell Technologies this week at